Federal Circuit Confirms Patent Eligibility of Gene Therapy Patent in Regenexbio Inc. v. Sarepta Therapeutics
Key Takeaway: Genetically engineered cultured host cells containing recombinant nucleic acids useful for gene therapy are patent-eligible for being markedly different from anything occurring in nature. In REGENXBIO Inc. v....
USPTO Director Signals Continued Pro-Patent Discretionary Denial Policy at the Patent Trial and Appeal Board
Key Takeaway: In a precedential decision in Magnolia Medical Technologies, Inc. v. Kurin, Inc., USPTO Director Squires denied IPR institution and reinforced the policy framework for discretionary denial at the...
Jeremiah Helm and Sean Murray Discuss Federal Circuit Decision on Patent Claim Language in Law360 Article
Knobbe Martens partners Jeremiah Helm and Sean Murray explored the Federal Circuit’s opinion on patent claim construction in Netflix Inc. v. DivX LLC in their latest Law360 column on the...